Let Your Patients Know.

CLINICAL TRIALS FOR FSGS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
EPPIK (Travere)	FSGS, MCD, IgAN, IgAV, Alport Syndrome	1-17	Sparsentan	≥ 30	2
DUPLEX (ENROLLMENT COMPLETE) (Travere)	FSGS	8–75	Sparsentan	≥ 30	3
THE PODO TRIAL (Pfizer)	FSGS	18+	PF-06730512	≥ 30	2
THE TRACTION-2 STUDY (Goldfinch Bio)	FSGS, treatment-resistant MCD, Lipoid Nephrosis, Diabetes Mellitus	18–75	GFB-887	≥ 30	2
STUDY OF VX-147 IN APOL1-MEDIATED PROTEINURIC KIDNEY DISEASE (Vertex)	Proteinuric Kidney Disease	18-60	VX-147	N/A	2/3
STUDY OF VX-147 IN APOL1-MEDIATED KIDNEY DISEASE (Vertex)	APOL1-Mediated FSGS	18–65	VX-147	≥ 30	2
AFFINITY (Chinook)	FSGS, IgAN, Alport Syndrome, DKD, Diabetic Nephropathy Type 2	18+	Atrasentan	≥ 30	2
STUDY OF BI 764198 IN FSGS (Boehringer Ingelheim)	FSGS	18-75	BI 764198	≥ 30	2
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	5–75	Liposorber LA-15 System	≥ 45 or post-transplant recurrence	N/A
TUMOR NECROSIS FACTOR INHIBITION IN FSGS AND TREATMENT-RESISTANT MCD (University of Michigan)	FSGS, MCD	6-70	adalimumab	> 45	2
STUDY OF VB119 IN STEROID-SENSITIVE PRIMARY MCD OR PRIMARY FSGS (ValenzaBio)	FSGS, MCD	18+	VB119	≥ 60	2
STUDY OF ANG-3070 IN PRIMARY GLOMERULAR DISEASE (Angion)	Glomerular Disease	18+	ANG-3070	≥ 40	2
STUDY OF BI 690517 ALONE AND IN COMBINATION WITH EMPAGLIFLOZIN IN DIABETIC AND NON-DIABETIC CKD (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 690517	≥ 30 & < 90	2
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90	2
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75	2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR FSGS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20	2
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20	3
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30	3
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90	3
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59	3
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29	2
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A	2
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A	3
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A	2
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A	2
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A	1 & 2
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A	1 & 2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR MCD PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
EPPIK (Travere)	MCD, FSGS, IgAN, IgAV, Alport Syndrome	1-17	Sparsentan	≥ 30	2
THE TRACTION-2 STUDY (Goldfinch Bio)	Treatment-resistant MCD, FSGS, Lipoid Nephrosis, Diabetes Mellitus	18–75	GFB-887	≥ 30	2
TUMOR NECROSIS FACTOR INHIBITION IN FSGS AND TREATMENT-RESISTANT MCD (University of Michigan)	Treatment-resistant MCD, FSGS	6-70	adalimumab	> 45	2
STUDY OF VB119 IN STEROID-SENSITIVE PRIMARY MCD OR PRIMARY FSGS (ValenzaBio)	MCD, FSGS	18+	VB119	≥ 60	2
STUDY OF ANG-3070 IN PRIMARY GLOMERULAR DISEASE (Angion)	Glomerular Disease	18+	ANG-3070	≥ 40	2
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90	2
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75	2
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20	3
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30	3
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90	3
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59	3
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29	2
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A	2
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A	3
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A	2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR MCD PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A	2
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A	1 & 2
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A	1 & 2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Let Your Patients Know.

CLINICAL TRIALS FOR IGAN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
EPPIK (Travere)	IgAN, FSGS, MCD, IgAV, Alport Syndrome	1-17	Sparsentan	≥ 30	2
SPARTAN (LEICESTER, UK) (Travere)	IgAN	18+	Sparsentan	≥ 30	2
PROTECT (ENROLLMENT COMPLETE) (Travere)	IgAN	18+	Sparsentan	≥ 30	3
AFFINITY (Chinook)	IgAN, FSGS, Alport Syndrome, DKD, Diabetic Nephropathy Type 2	18+	Atrasentan	≥ 30	2
ALIGN (Chinook)	IgAN	18+	Atrasentan	≥ 30	3
SAFETY & TOLERABILITY OF BION-1301 IN HEALTHY VOLUNTEERS & ADULTS WITH IGAN (CALIFORNIA, EL PASO TEXAS, LONDON) (Chinook)	IgAN	18+	BION-1301	≥ 30	1 & 2
VISIONARY (Otsuka)	IgAN	18+	Sibeprenlimab	≥ 30	3
SAFETY & EFFICACY OF VIS649 FOR IGAN (ENROLLMENT COMPLETE) (Visterra)	IgAN	18+	VIS649	≥ 45	2
STUDY OF BI 690517 ALONE AND IN COMBINATION WITH EMPAGLIFLOZIN IN DIABETIC AND NON-DIABETIC CKD (Boehringer Ingelheim)	IgAN, FSGS, MN, DKD, Hypertensive Kindey Disease	18+	BI 690517	≥ 30 and < 90	2
APPLAUSE-IGAN (Novartis)	IgAN	18+	LNP023	≥ 20	3
ORIGIN (Vera)	IgAN, Berger Disease	18+	Atacicept	≥ 30	2
NEFIGARD (ENROLLMENT COMPLETE) (Calliditas)	IgAN	18+	Nefecon	≥ 35	3
THE DISCOVERY TRIAL (ENROLLMENT COMPLETE) (Apellis)	IgAN, MN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30	2
SANCTUARY (Alexion)	IgAN, Lupus Nephritis	18-75	Ravulizumab	≥ 30	2
STUDY OF ALXN2050 IN IGAN & PROLIFERATIVE LUPUS NEPHRITIS (Alexion)	IgAN, Lupus Nephritis	18-75	ALXN2050	> 30	2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR IGAN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
TELITACICEPT FOR INJECTION (RC18) IN IGAN (RemeGen)	IgAN	18-70	Telitacicept	> 30	2
THE ARTEMIS-IGAN STUDY (Omeros)	IgAN	18+	Narsoplimab/ OMS721	≥ 30	3
IGNAZ (MorphoSys)	IgAN	18-80	Felzartamab	UPCR: ≥ 1.0	2
STUDY OF CEMDISIRAN IN ADULTS WITH IGAN (ENROLLMENT COMPLETE) (Alnylam)	IgAN	18–65	Cemdisiran	≥ 30	2
EFFECTIVENESS & SAFETY OF IONIS-FB-LRX IN IGAN (AUSTRALIA, CANADA, NEW ZEALAND) (Ionis)	IgAN	18–75	IONIS-FB-LRx	> 40	2
RENEW (ENROLLMENT COMPLETE) (BioCryst)	IgAN, C3G, MN	18+	BCX9930	≥ 50	2
SAFETY AND EFFICACY OF AT-1501 IN IGA NEPHROPATHY (Eledon)	IgAN	18-99	AT-1501	≥ 30	2
SAFETY AND TOLERABILITY OF MEZAGITAMAB (TAK-079) IN IGAN WITH STABLE BACKGROUND THERAPY (Takeda)	IgA Nephropathy, IgAV	18+	Mezagitamab	≥ 45	1
STUDY OF ANG-3070 IN PRIMARY GLOMERULAR DISEASE (Angion)	Glomerular Disease	18+	ANG-3070	≥ 40	2
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90	2
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75	2
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20	2
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20	3
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30	3
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90	3

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR IGAN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59	3
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29	2
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A	2
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A	3
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A	2
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A	2
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A	1 & 2
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A	1 & 2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Let Your Patients Know.

CLINICAL TRIALS FOR MEMBRANOUS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
EFFICACY & SAFETY OF LNP023 COMPARED WITH RITUXIMAB IN ADULTS WITH IDIOPATHIC MN (Novartis)	MN	18+	LNP023, Rituximab	≥ 30	2
THE DISCOVERY TRIAL (ENROLLMENT COMPLETE) (Apellis)	MN, IgAN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30	2
A PHASE IB/2A STUDY OF VB119 IN PRIMARY MN (ValenzaBio)	MN	18+	VB119	≥ 45	1 & 2
NEW-PLACE (ENROLLMENT COMPLETE) (MorphoSys)	MN	18-80	MOR202	> 30	2
MONET (ITALY) (MorphoSys)	MN	18+	MOR202	> 30	2
M-PLACE (ENROLLMENT COMPLETE) (MorphoSys)	MN	18-80	MOR202	≥ 30	1 & 2
REBOOT (NIAID)	MN, Nephrotic Syndrome	18-75	Belimumab, Rituximab	≥ 30	2
EFFICACY & SAFETY OF OBINUTUZUMAB IN PARTICIPANTS WITH PRIMARY MN (Hoffmann-La Roche)	MN	18-75	Obinutuzumab	≥ 30	3
RENEW (ENROLLMENT COMPLETE) (BioCryst)	MN, IgAN, C3G	18+	BCX9930	≥ 50	2
STUDY OF ANG-3070 IN PRIMARY GLOMERULAR DISEASE (Angion)	Glomerular Disease	18+	ANG-3070	≥ 40	2
STUDY OF BI 690517 ALONE AND IN COMBINATION WITH EMPAGLIFLOZIN IN DIABETIC AND NON-DIABETIC CKD (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 690517	≥ 30 & < 90	2
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90	2
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75	2
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20	2
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20	3

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR MEMBRANOUS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30	3
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90	3
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59	3
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29	2
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A	2
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A	3
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A	2
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A	2
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A	1 & 2
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A	1 & 2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR C3G PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
APPEAR-C3G (Novartis)	C3G	18–60	LNP023	≥ 30	3
VALIANT (Apellis)	C3G, IC-MPGN, C3GN, DDD, MPGN	12+	Pegcetacoplan	≥ 30	3
THE NOBLE STUDY (Apellis)	C3G, C3GN, DDD, MPGN, or IC-MPGN that has recurred after	18+	Pegcetacoplan	≥ 15	2
THE DISCOVERY TRIAL (ENROLLMENT COMPLETE) (Apellis)	C3G, Dense Deposit Disease, IgAN, MN, or Lupus Nephritis	18+	APL-2	≥ 30	2
RENEW (ENROLLMENT COMPLETE) (BioCryst)	C3G, MN, IgAN	18+	BCX9930	≥ 50	2
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90	2
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75	2
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20	2
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20	3
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30	3
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90	3
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59	3
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29	2
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A	2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR C3G PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A	3
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A	2
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A	2
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A	1 & 2
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A	1 & 2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR C3GN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
THE NOBLE STUDY (Apellis)	C3GN, C3G, DDD, MPGN, or IC-MPGN that has recurred after	18+	Pegcetacoplan	≥ 15	2
VALIANT (Apellis)	C3GN, C3G, IC-MPGN, DDD, MPGN	12+	Pegcetacoplan	≥ 30	3
THE DISCOVERY TRIAL (ENROLLMENT COMPLETE) (Apellis)	C3GN, C3G, IC-MPGN, DDD, MPGN	18+	Pegcetacoplan	≥ 30	2
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90	2
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75	2
ZENITH-CKD (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20	2
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20	3
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30	3
FIND-CKD (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90	3
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59	3
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29	2
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A	2
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A	3
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A	2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR C3GN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A	2
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A	1 & 2
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A	1 & 2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Let Your Patients Know.

CLINICAL TRIALS FOR MPGN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
THE NOBLE STUDY (Apellis)	MPGN, IC-MPGN, C3GN, C3G, or DDD, or any of these conditions that has recurred after kidney transplant	18+	Pegcetacoplan	≥ 15	2
VALIANT (Apellis)	MPGN, IC-MPGN, C3G, C3GN, DDD	12+	Pegcetacoplan	≥ 30	3
STUDY OF ANG-3070 IN PRIMARY GLOMERULAR DISEASE (Angion)	Glomerular Disease	18+	ANG-3070	≥ 40	2
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (Boehringer Ingelheim)	Chronic Kidney Disease	18+	BI 685509	≥ 20 & < 90	2
STUDY OF AZD5718 IN PROTEINURIC CKD (AstraZeneca)	Chronic Kidney Disease	18+	AZD5718, Dapagliflozin	20-75	2
ZENITH-CKD (ENROLLMENT COMPLETE) (AstraZeneca)	Chronic Kidney Disease	18+	Zibotentan Dapagliflozin	≥ 20	2
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20	3
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 to 17	Finerenone (Kerendia, BAY94-8862)	≥ 30	3
STUDY OF FINERENONE IN NON-DIABETIC CHRONIC KIDNEY DISEASE (Bayer)	Chronic Kidney Disease	18+	Finerenone (BAY94-8862)	≥ 25 and < 90	3
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59	3
SAFETY AND EFFICACY OF APR2020 IN CKD STAGE IV (Kibow)	Chronic Kidney Disease Stage IV	18-80	US-APR2020	15-29	2
PREVENTION OF ARTERIOVENOUS GRAFT THROMBOSIS AND SAFETY OF MK-2060 IN PATIENTS WITH ESRD RECEIVING HEMODIALYSIS (Merck Sharpe & Dohme)	End Stage Renal Disease & Kidney Failure	18+	MK-2060	N/A	2
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A	3
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A	2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR MPGN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A	2
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A	1 & 2
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	N/A	1 & 2

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Let Your Patients Know.

CLINICAL TRIALS FOR TRANSPLANT PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A	3
FREEDOM-2 (Talaris)	De novo living donor transplant (3-12 months after transplant)	18+	FCR001	N/A	2
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A	N/A
AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS IN RENAL TRANSPLANT RECIPIENTS (Novartis)	De novo living donor transplant	18-65	Apheresis	N/A	N/A
STUDY OF VIB4920 AND BELATACEPT FOR PROPHYLAXIS OF ALLOGRAFT REJECTION IN KIDNEY TRANSPLANT (ENROLLMENT COMPLETE) (Horizon Therapeutics/Viela Bio)	De novo transplant	18-70	VIB4920 & Belatacept	N/A	2
THE NOBLE STUDY (Apellis)	MPGN, IC-MPGN, C3GN, C3G, or DDD, or any of these conditions	18+	Pegcetacoplan	≥ 15	3
VALIANT (Apellis)	MPGN, IC-MPGN, C3G, C3GN, DDD	12+	Pegcetacoplan	≥ 30	N/A
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	5–75	Liposorber LA-15 System	≥ 45 or post-transplant recurrence	1 & 2
T CELL MODULATION IN KIDNEY TRANSPLANTATION WITH BIOLOGIC BLOCKADE OF DUAL EFFECTOR PATHWAYS, CD28 & IL-6 (CTOT-24) (ENROLLMENT COMPLETE) (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	1 & 2	2
STEADFAST (Sangamo Therapeutics)	Kidney transplant rejection	18-70	TX200-TR101	1 & 2	

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.

Trial Table Updated Monthly on NephCure.org/TrialTable

Let Your Patients Know.

CLINICAL TRIALS FOR PEDIATRIC PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN	PHASE
EPPIK (Travere)	FSGS, MCD, IgAN, IgAV, Alport Syndrome	1-17	Sparsentan	≥ 30	2
DUPLEX (ENROLLMENT COMPLETE) (Travere)	FSGS	8–75	Sparsentan	≥ 30	3
VALIANT (Apellis)	C3G, IC-MPGN, C3GN, DDD, MPGN	12+	Pegcetacoplan	≥ 30	3
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	5–75	Liposorber LA-15 System	≥ 45 or post-transplant recurrence	N/A
TUMOR NECROSIS FACTOR INHIBITION IN FSGS AND TREATMENT-RESISTANT MCD (University of Michigan)	FSGS, MCD	6-70	adalimumab	> 45	2
EAGLE (Reata)	Chronic Kidney Disease, Alport Syndrome	12+	Bardoxolone methyl	≥ 20	3
FIONA - STUDY OF FINERENONE IN ADDITION TO AN ACEI OR ARB FOR CHILDREN 6 MONTHS TO < 18 YEARS OF AGE WITH CKD (Bayer)	Chronic Kidney Disease	6 months to 17 years	Finerenone (Kerendia, BAY94-8862)	≥ 30	3
STUDY OF HECTOROL IN PEDIATRIC PATIENTS WITH CKD STAGES 3 AND 4 WITH HYPERPARATHYROIDISM NOT ON DIALYSIS (ENROLLMENT COMPLETE) (Sanofi)	Secondary Hyperparathyroidism Chronic Kidney Disease	5-18	Doxercalciferol (GZ427397)	15-59	3

Visit **KidneyHealthGateway.com** to play your part in cutting-edge kidney research.

NEPHCURE® Kidney International

This is a living document and was last updated on 7/18/22.